R&D Trends

Report: Type 2 diabetes population to expand in China

Wednesday, December 10, 2014 01:01 PM

For the treatment of type 2 diabetes in China, patient access to premium-priced agents is impeded as not all patients can afford these drugs, Burlington, Mass.-based Decision Resources Group has found. The National Reimbursement Drug List was last updated in 2009, and several antidiabetic drug classes (e.g. DPP-IV inhibitors and GLP-1 receptor agonist) are not covered, as they were only approved for use in China after 2009.

More... »


Agilent Technologies, Baylor College of Medicine open Center of Excellence

Monday, December 8, 2014 01:06 PM

Agilent Technologies, headquartered in Santa Clara, Calif., and Houston, Texas-based Baylor College of Medicine have opened the Agilent Technologies Mass Spectrometry Center of Excellence as part of the Alkek Center for Molecular Discovery and the Baylor College of Medicine Core Laboratory in the college's department of molecular and cellular biology.

More... »


Aldeyra Therapeutics, National Organization for Rare Disorders collaborate

Monday, December 8, 2014 01:04 PM

Aldeyra Therapeutics, a Massachusetts-based biotechnology company focused on the development of products to treat diseases related to free aldehydes, is collaborating with the National Organization for Rare Disorders (NORD), a U.S. nonprofit organization dedicated to helping people with rare diseases.

More... »

Pharmacyclics launches informCLL registry for CLL patients

Friday, December 5, 2014 12:37 PM

Pharmacyclics, a Sunnyvale, Calif.-based biopharmaceutical company, has launched informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how Imbruvica (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL and provide a comparison to treatments using conventional chemoimmunotherapy (CIT). Imbruvica is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, and the registry is a joint effort between the companies. Registry enrollment will begin in the first half of 2015.

More... »

ALS Association, Muscular Dystrophy Association partner

Friday, December 5, 2014 12:33 PM

The ALS Association, a national nonprofit based in Wash. D.C., and the Muscular Dystrophy Association (MDA), a Chicago-based nonprofit health agency, have joined forces to fund a research project aimed at finding a potential therapy for amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease. Both nonprofits are focused on finding treatments and cures for ALS and providing services for those affected with the debilitating, fatal disease.  

More... »

Report: Parkinson’s treatment pipeline targeting functional processes over genes

Thursday, December 4, 2014 12:35 PM

The Parkinson’s disease (PD) treatment pipeline is characterized by a high degree of innovation and diverse molecular targets, with 37% of 302 products holding first-in-class status, according to New York-based business intelligence provider GBI Research.

More... »

NIH awards $20M for drug delivery system to prevent HIV infection in women

Thursday, December 4, 2014 12:30 PM

The University of Texas Medical Branch (UTMB) is part of a collaboration led by the Oak Crest Institute of Science that received a $20 million grant from the NIH to develop a novel intravaginal ring capable of delivering powerful antiretroviral drugs to prevent the spread of sexually transmitted HIV in women. The total award to UTMB is approximately $2.5 million.

More... »

Diagnostics Development Hub to boost biomedical research in Singapore

Thursday, December 4, 2014 12:25 PM

Singapore's biomedical research sector received a major boost with the launch of a new Diagnostics Development (DxD) Hub. The DxD Hub aims to develop medical diagnostics as one part of the medical technologies industry, improve healthcare through development of diagnostic solutions and accelerate production of new diagnostics devices. Diagnostics is one of four innovation clusters shortlisted to be funded under the $200 million Innovation Cluster Program (ICP) launched Oct. 2013.

More... »

Report: Global stem cell market to reach $118B by 2018

Wednesday, December 3, 2014 01:02 PM

The global stem cell market earned revenues of $40.01 billion in 2013 and is estimated to nearly triple to $117.66 billion in 2018 at a compound annual growth rate (CAGR) of 24.1%, according to a new analysis from Frost & Sullivan. The study covers human adult and embryonic stem cells. While North America is the market leader with more than half of the global stem cell market share, Asia-Pacific is expected to record the highest CAGR during the forecast period. In fact, the APAC stem cell market, which was valued at $5.6 billion in 2013, is projected to increase to $18.71 billion by 2018.

More... »

Seattle Children's launches $100M fundraising initiative to cure childhood cancer

Wednesday, December 3, 2014 01:01 PM

Seattle Children's Hospital and Research Foundation has launched a $100 million, multi-year fundraising initiative to support research that scientists believe has the ability to cure some types of childhood cancer in the next five to 10 years.

More... »

CenterWatch
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs